OpenAI acquiert Orchestra Bio

OpenAI has acquired Orchestra Bio, a platform designed to help biopharma teams coordinate the complex process of drug development. The acquisition brings Orchestra's team and technology together with Rosalind, OpenAI's existing life sciences research initiative. Together, the combined effort aims to build AI agents that assist researchers in connecting scientific discoveries with clinical studies and regulatory workflows.